Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022104 (irritable bowel syndrome)
 8,033 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Irritable Bowel Syndrome (IBS) refers to a collection of gastrointestinal symptoms which affect up to 22% of the Western population. Although the disorder costs the British National Health Service and employers vast sums of money in terms of repeated physician visits, medications, and loss of productivity, the cause or causes of IBS are still unknown, and there is no cure which is lastingly effective. Since IBS is not life-threatening, and the symptoms can be hidden from others, many consider it a trivial disorder. For an individual with IBS, however, the uncertainty regarding cause, diagnosis and treatment may lead to anxiety and constant searching for causes, or to hopelessness and resignation. The present study aims to help clarify these problems by discovering how those who suffer from IBS understand the nature and causality of their own illness. Through use of Q methodology with a sample of 60 people with IBS, a taxonomy of 7 clear and distinct accounts is identified and described. These data (based on Q factor analysis) are described in qualitative detail and discussed in relation to the problem of improving communication with doctors, and untangling issues of responsibility for illness.
 ...
PMID:The understanding of their illness amongst people with irritable bowel syndrome: a Q methodological study. 1085 30

This study was conducted to determine the dietary supplement (DS) use in gastrointestinal symptom management, and its effect on hopelessness levels in patients with irritable bowel syndrome (IBS). The universe of this cross-sectional study consisted of 132 patients presenting at the polyclinic, while the sample consisted of 127 patients who meet the inclusion criteria to study. Data were collected using a patient identification form including sociodemographic characteristics and DS use, the Gastrointestinal Symptom Rating Scale, and the Beck Hopelessness Scale. The frequency of DS use in the last year among patients with IBS was 73.2%. Younger, women, those with graduate education, and those with better economic status were found to prefer more DS (P < .0001). Nausea and decreased passage of stools were predictors of DS use with a rate of 40.9% (R = 0.409, P < .0001). The patients were found to use mint oil (35.6%), mint juice (24.6%), lemon (20.5%) for nausea, and apricots (48.2%) and dietary fibers (16.9%) for decreased passage of stools. Patients who did not use DSs were found to be more hopeless (P < .03). It was found that 73.2% of patients with IBS used DSs. Patients who did not use DSs were found to be more hopeless. DSs with proven effectiveness can be integrated into medical treatments.
 ...
PMID:Dietary Supplement Use in Gastrointestinal Symptom Management and Effect on Hopelessness Levels in Patients With Irritable Bowel Syndrome. 3097 35